Principal Financial Group Inc. Takes $267,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Principal Financial Group Inc. bought a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) during the third quarter, Holdings Channel.com reports. The institutional investor bought 20,294 shares of the company’s stock, valued at approximately $267,000.

Several other hedge funds also recently bought and sold shares of YMAB. Dimensional Fund Advisors LP raised its stake in shares of Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares during the period. Millennium Management LLC boosted its position in shares of Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after purchasing an additional 67,233 shares during the period. Squarepoint Ops LLC increased its holdings in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the last quarter. Bank of New York Mellon Corp raised its position in Y-mAbs Therapeutics by 8.0% in the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after purchasing an additional 8,974 shares during the period. Finally, Rice Hall James & Associates LLC lifted its stake in Y-mAbs Therapeutics by 21.1% during the third quarter. Rice Hall James & Associates LLC now owns 108,684 shares of the company’s stock worth $1,429,000 after purchasing an additional 18,949 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Up 1.4 %

Shares of Y-mAbs Therapeutics stock opened at $10.56 on Tuesday. The company has a market capitalization of $472.98 million, a P/E ratio of -19.56 and a beta of 0.68. The company has a 50 day moving average of $13.69 and a 200 day moving average of $12.84. Y-mAbs Therapeutics, Inc. has a 52-week low of $5.31 and a 52-week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the prior year, the firm posted ($0.18) EPS. As a group, research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The trade was a 30.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on YMAB. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. BMO Capital Markets dropped their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.38.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.